Bringing proven ECP therapy to more patients – efficiently, affordably, at scale

Wave PRO^TM is a scalable cardiovascular therapy designed for safety, simplicity, and measurable patient benefit. Its portable, reimbursable, and clinically validated design integrates seamlessly into outpatient service lines, supported by a low-cost lease model that minimizes capital expenditure.

Wave PRO^TM adds measurable cardiac benefit without major infrastructure or staffing increases

A Revenue-Positive Therapy Enabling Expanded CSA Treatment

As healthcare systems seek to expand non-invasive cardiac options without complex overhead, the Pression Wave PRO^TM offers a practical solution.

Its small footprint (24”x24”), portable form factor (just 34 kg) and automated therapy delivery make it ideal for outpatient centers, rehab programs, and community health settings. Each unit delivers proven hemodynamic outcomes 1 and rapid ROI potential.

Value to the Institution

Wave PRO^TMexpands non-invasive ECP therapy options by offering an automated, software-guided therapy designed for scalable, resource-efficient delivery, requiring minimal maintenance and backed by a full warranty.

Overview

Non-surgical therapy option for patients with drug-refractory CSA and no revascularization options 1
More capital-efficient, space efficient and staff efficient alternative compared to legacy ECP systems
Expands service offerings without additional infrastructure
One-hour treatment sessions with minimal staffing requirements 1
Durable, reusable sleeves with minimal upkeep as part of a complete turnkey system with full warranty and dedicated support for uninterrupted operation
Reimbursable under HCPCS code G0166 5 , ensuring straightforward integration into clinical billing and reimbursement workflows

Clinical Perfomance

Calf only pulse synchronized compression delivering diastolic augmentation and systolic unloading 1
Streamlined setup designed to minimize preparation time and staff burden
WAVECRESST study demonstrated equivalent hemodynamic benefit and improved patient comfort 1

Regulatory & Safety

FDA-cleared through the WAVECRESST clinical trial 1
Built under a comprehensive quality and risk-management program
Rigorously tested to industry standards

Economic & Strategic Value

Adds reimbursable therapy for Chronic Stabile Angina (CSA) 5
Diversifies cardiovascular and wellness service lines
Portable system allows flexible deployment
Turnkey solution featuring full warranty on all components with hassle-free replacement of all elements including worn-out sleeves
Low start up cost through a monthly lease model that eliminates major capital expenditure and minimizes ongoing operating costs

Operational Advantages

Small footprint (24”x24”), portable form factor (just 34 kg). Plug-and-play setup with existing compressed air infrastructure
Efficient personnel usage: short training duration and automated therapy delivery (PPG sensor and intelligent timing algorithm) after setup with the patient
Engineered for a quieter experience than conventional ECP therapy with low-maintenance operation
60-minute sessions enable efficient scheduling

Onsite Implementation

Pression provides onboarding, staff training, marketing collateral for referring physicians and reimbursement education to streamline adoption and ensure measurable ROI.

Clinical Confidence

The Pression Wave PRO^TM is clinically proven in the United States to offer equivalent diastolic augmentation 1 and compliant with IEC 60601 and ISO 14971 standards.